Previously the company announced 26-week data that tracked a sub-population living with the muscle-specific kinase autoantibody-positive (MuSK+) variant of the disease. In those results ...

The Phase 3 MINT trial, which was a randomized-control trial, evaluated Uplinza in muscle-specific kinase autoantibody-positive and AChR+ gMG patients, with the MuSK+ group followed for 26 weeks ...

including 190 patients who were AChR+ and 48 patients who were muscle-specific kinase autoantibody-positive (MuSK+). Patients were eligible for the study if they had Myasthenia Gravis Foundation ...

The MINT trial, a randomized-control study, followed AChR+ gMG patients for a year and muscle-specific kinase autoantibody-positive (MuSK+) gMG patients for 26 weeks. Results indicated a ...

The MINT trial, a randomized-control study, followed AChR+ gMG patients for a year and muscle-specific kinase autoantibody-positive (MuSK+) gMG patients for 26 weeks. Results indicated a significant ...

The trial enrolled 238 adults from 104 international sites, comprising 190 patients in the AChR+ group and 48 patients in the MuSK+ group. Credit: shutterstock / CGN089. Amgen’s Uplizna ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Report a crime or incident, such as an accident on the road, lost and found property, or anti-social behaviour.